申请人:American Home Products Corporation
公开号:US06380178B1
公开(公告)日:2002-04-30
This invention relates to cyclic combination therapies and regimens utilizing, in combination with progestins, substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure:
where A and B are independent substituents selected from S, CH or N; provided that when A is S, B is CH or N; and when B is S, A is CH or N; and A and B cannot both be CH; and when A and B both equal N, one N may be optionally substituted with an C1 to C6 alkyl group; R1 and R2 are independent substituents selected from the group of H, C1 to C6 alkyl, substituted C1 to C6 alkyl, C2 to C6 alkenyl, substituted C2 to C6 alkenyl, C2 to C6 alkynyl, substituted C2 to C6 alkynyl, C3 to C8 cycloalkyl, substituted C3 to C8 cycloalkyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, CORA, or NRBCORA; or R1 and R2 are fused to form optionally substituted 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic ring, the heterocyclic ring containing one to three heteroatoms selected from the group of O, S and N; or pharmaceutically useful salts thereof. These methods of treatment may be used for contraception.
本发明涉及循环联合疗法和方案,其中与孕激素联合使用的取代吲哚啉衍生物化合物作为孕激素受体的拮抗剂,其具有一般结构:其中A和B是独立的取代基,选择自S、CH或N;前提是当A为S时,B为CH或N;当B为S时,A为CH或N;A和B不能同时为CH;当A和B均等于N时,一个N可以选择性地被取代为C1至C6烷基;R1和R2是独立的取代基,选择自H、C1至C6烷基、取代C1至C6烷基、C2至C6烯基、取代C2至C6烯基、C2至C6炔基、取代C2至C6炔基、C3至C8环烷基、取代C3至C8环烷基、芳基、取代芳基、杂环、取代杂环、CORA、或NRCORA;或者R1和R2被融合形成可选择性取代的3至8个成员的螺环烷基、烯基或杂环,其中杂环含有选自O、S和N的一到三个杂原子;或其药用盐。这些治疗方法可用于避孕。